Future Market Dynamics in Type 2 Diabetes: Boehringer Ingelheim.
As a Boehringer Ingelheim staff member you are invited to attend this special diabetes market webinar
By Rajan Sharma, Senior Analyst
I joined Datamonitor Healthcare in late in 2013 after completing a Masters in Pharmacology from the University of Oxford...
Read full bio
2015 will see the type 2 diabetes market subject to unprecedented change due to the entry of the first basal insulin biosimilars. However, due to the use of more expensive therapies in place of generics at second and third lines of therapy the market will continue to grow over the next ten years.
So how can you ensure you stand out in this increasingly competitive market? We would like to personally invite employees of Boehringer Ingelheim to join Datamonitor Healthcare analyst, Rajan Sharma on Thursday, 19 February at 3pm (GMT) to increase your understanding of future market dynamics.
We will explore this market area through our detailed analysis, which will cover:
- Key factors driving market growth to 2023
- Key treatment trends and how these will affect market dynamics
- The impact of insulin glargine biosimilars on the market
- Positioning of Eli Lilly’s much anticipated Trulicity within the GLP-1 agonist market
- and much more…